Peripheral vascular disease is associated with OP and hip fractures. #ACR18 @RheumNow Abstract 2305. pic.twitter.com/VhFz3KzLNY
— William Shergy (@WilliamShergy) October 23, 2018
2323 survival after hip fragility fract in OP: ⬇️ survival in pts >=80 yo,partially & totally dependent pts& pts w/ ⬆️ serum beta-crosslaps (HR 4.27, p=0.007). Higher femur BMD& T-score predict better survival. Gender, surgery, vit D& ostecalcin had no effect. #acr18 @rheumnow
— Olga Petryna (@DrPetryna) October 23, 2018
How to deal with the complications of OP therapy. #ACR18 @RheumNow Abstract 4M092 pic.twitter.com/ZvzbBNR162
— William Shergy (@WilliamShergy) October 22, 2018
#ACR18 Plenary II:
#1818 Dr Saag – denosumab vs risedronate in GC-treated patients, 24 month data. Denosumab clearly better for BMD improvement. But beware surrogate outcome measures (no diff in fractures, but not powered for this). No diff in AEs (inc infection). @RheumNow pic.twitter.com/PpfSYzthey— ǝlʇʇıɥʍ ɯɐs (@samwhittle) October 22, 2018